NEW YORK – Oncology firm Indivumed said Monday that it has partnered with Biognosys to add proteomic and phosphoproteomic data to its IndivuType multi-omics cancer database.
Under the partnership, Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's database, which also contains genomic, transcriptomic, immunophenotypic, and clinical and outcome data.
"Proteomics and phosphoproteomics play a crucial role in understanding cancer biology, and adding Biognosys' technology to the IndivuType multi-omics profile will enable relevant discoveries in our collaborations with pharma and biotech," Hartmut Juhl, Indivumed's founder and CEO, said in a statement.
"With the development of the parallel acquisition-based next-generation technology, proteomics has become both more sensitive and higher throughput," said Oliver Rinner, Biognosys CEO and founder. "We are convinced that large-scale proteomics and phosphoproteomics data from well characterized sample cohorts will add a highly relevant new dimension to quantitative biology, and specifically to cancer biology."
Financial and other details of the partnership were not disclosed.